August 2025

ProVerum Secures $80 Million Series B Financing to Advance New Treatment for BPH

 

April 2025

ProVerum Welcomes Tyler Binney to the Board of Directors

 

April 2025

Investigational ProVee System impressed in phase 3 trial in BPH

 

March 2024

Completion of Enrollment for the ProVIDE Clinical Study

ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

 

June 2022

First Enrollment in the ProVIDE Clinical Study

ProVerum Ltd. announces first patient enrolled in ProVIDE Study.

 

January 2022

ProVerum Ltd. Raises €30M in Series A Funding

ProVerum Ltd. announces the closing of a €30 million Series A equity financing co-led by Gilde Healthcare Partners and Lightstone Ventures.

 

December 2021

ProVerum Ltd. Receives IDE approval for ProVIDE Study

ProVerum Ltd. announces approval from the U.S. Food and Drug Administration (FDA) to support initiating an investigational device exemption (IDE) to evaluate the safety and affectiveness of the ProVee Urethral Expander System.

 

December 2020

ProVerum closes further equity funding

ProVerum Ltd. closes a further round of equity investment from its existing investors. The round was led by Atlantic Bridge.

 

June 2020

ProVerum’s Founders nominated for EY Entrepreneur of the Year
Now in its 23rd year, the prestigious EY Entrepreneur of the Year awards works to recognize, promote and build a supportive community around Ireland’s high-growth entrepreneurs. 

 

March 2020

ProVerum receives €2.5M from Horizon 2020

ProVerum Ltd. has been awarded a grant of €2.5m via the EU funded H2020 EIC Accelerator project instrument. This 2-year project will fund a EU pivotal clinical trial, CE Mark approval and further commercialization.